All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma Hub
Brought to you by Scientific Education Support

The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

EHA 2019 | GOYA trial: Prognostic value of metabolic tumor volume in DLBCL

By Emily Smith,Marek Trněný

Share:

Featured:

Marek TrněnýMarek Trněný

Jun 19, 2019

At the 24th Congress of the European Hematology Association (EHA), Marek Trněný from the Charles University General Hospital, Prague, CZ, talks about GOYA trial and the prognostic value of metabolic tumor volume in diffuse large B-cell lymphoma (DLBCL).

Marek Trněný highlights one of the main questions in the field; how do we manage patients failing therapy and how can we define refractory patients? Whilst the GOYA study was negative, one thing the group evaluated was how to identify refractory patients or those at risk of early relapse (within 12 months).
 
One method to do this was to measure total metabolic tumor volume. The group found that patients in 4th quartile had a higher chance of developing refractory disease and so defined a cut-off to predict this. It was concluded that if this cut-off is applied to daily practice, it may be possible to start subsequent treatment earlier or use more intensive treatment in these patients.

GOYA trial: Prognostic value of metabolic tumor volume in DLBCL

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

Diffuse large B-cell lymphomaEHA 2019ObinutuzumabRituximabGOYAAggressive B-cell lymphomasAntibody therapyEuropean Hematology Association

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.

Your opinion matters

When selecting the next therapy for patients with R/R MCL after BTKi progression, what is your most important consideration?

Newsletter

Subscribe to get the best content delivered to your inbox